Tempus AI

Tempus AI Cash Flow per Share

The Operating Cash Flow per Share of Tempus AI (TEM) as of Nov 2, 2026 is -1.25 USD. In the previous year, Operating Cash Flow per Share was -1.17 USD — a change of 7.33% (lower).

Cash Flow per Share

-1.25USD

YoY

7.33%

Last updated:

Operating Cash Flow per Share of Tempus AI is 2025 -1.25 USD. Operating Cash Flow per Share of Tempus AI was 2024 -1.17 USD. It decreases by 7.33% lower compared to the previous year.

The Tempus AI Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2019
-0.73 USD
Jan 1, 2020
-3.29 USD
Jan 1, 2021
-1.25 USD
Jan 1, 2022
-0.99 USD
Jan 1, 2023
-1.39 USD
Jan 1, 2024
-1.17 USD
Jan 1, 2025
-1.25 USD
The Tempus AI Cash Flow per Share history
YEARCash Flow per ShareYoY
-1.25USD+7.33%
-1.17USD-16.12%
-1.39USD+40.41%
-0.99USD-20.65%
-1.25USD-62.03%
-3.29USD+351.03%
-0.73USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Operating Cash Flow per Share of Tempus AI is -1.25 USD in 2025.

Operating Cash Flow per Share of Tempus AI changed from -1.17 USD to -1.25 USD, representing a 7.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Tempus AI since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tempus AI

All Key Metrics — Tempus AI